Frequency of HLA-Class I and Class II Homozygous cells in Japanese. HLA-Homozygous cells related to factor inducing transfusion-associated Graft Versus Host Disease.

洋行, 稲葉; 延夫, 荒木; 泰光, 浜中; 宣彦, 阪田; 英俊, 猪子; 義介, 能勢

doi:10.3925/jjtc1958.41.1

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The source of stem cells and the prophylaxis regimen for GVHD might be important factors to consider to avoid severe GVHD in HCT from an HLA‐homozygous donor. The present patient was not Japanese; however, the Japanese population has relatively well‐conserved haplotypes with high frequencies, and approximately 1% of the Japanese population is HLA homozygous . Therefore, homo‐to‐hetero CBT is not so rare a procedure.…”

Section: Discussionmentioning

confidence: 71%

Successful engraftment after cord blood transplantation from an HLA‐homozygous donor (homo‐to‐hetero cord blood transplantation) in a primary myelofibrosis patient with broad HLA antibodies

et al. 2018

View full text Add to dashboard Cite

BACKGROUND: Donor-specific human leukocyte antigen (HLA) antibodies are a significant risk factor for graft failure in cord blood transplantation (CBT). Although there are several treatments to decrease HLA antibodies, such as platelet transfusion, plasma exchange, rituximab, and bortezomib, their effectiveness has not been established. STUDY DESIGN AND METHODS:We herein report the case of a primary myelofibrosis (PMF) patient with broad HLA antibodies who underwent CBT from an HLAhomozygous donor in which the alleles were matched only in the host-versus-graft direction (homo-tohetero CBT). RESULTS:The cord blood was killer cell immunoglobulin-like receptor (KIR) ligand matched. She received a reduced-intensity conditioning regimen. We used tacrolimus and mycophenolate mofetil as prophylaxis against graft-versus-host disease (GVHD). The neutrophils engrafted on Day 31. A chimerism analysis with fluorescence in situ hybridization of peripheral blood cells showed 99.9% donor type on Day 33. She developed only mild acute skin GVHD and chronic skin GVHD. CONCLUSION: This case indicates the usefulness ofhomo-to-hetero CBT in a patient with broad HLA antibodies with a strong mean fluorescence intensity, which is a significant risk factor for graft failure. Further studies are necessary to determine the risk of GVHD and to elucidate the association between KIR ligand incompatibility and graft failure in homo-to-hetero CBT. ABBREVIATIONS: CBT = cord blood transplantation; HCT = hematopoietic cell transplantation; KIR = killer cell immunoglobulin-like receptor; PMF = primary myelofibrosis; TAC = tacrolimus.From the

show abstract

Section: Discussionmentioning

confidence: 71%

Successful engraftment after cord blood transplantation from an HLA‐homozygous donor (homo‐to‐hetero cord blood transplantation) in a primary myelofibrosis patient with broad HLA antibodies

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Such HLA-homozygous parental donors should therefore be avoided [30]. The HLA-homozygous entity occurs at 3.2% in Japan, which is higher than in other countries, attributable to the homogeneous ethnicity [31]. Consequently, preoperative HLA-DNA typing is strongly recommended for combinations carrying a suspected risk of GVHD in the LDLT setting [32].…”

Section: Key Pointsmentioning

confidence: 99%

Marginal parental donors for pediatric living donor liver transplantation

Kasahara

Sakamoto

Fukuda

et al. 2022

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewLiving donor liver transplantation (LT) has been increasingly recognized as an effective treatment modality with excellent patient survival. Indications for LT have evolved not only for cholestatic liver disease, but also metabolic liver diseases. Living donor selection, particularly for pediatric inherited disease, is essential to prevent morbidity, both in the donor and recipient. Recent findingsBased on 30 years of experience in pediatric living donor LT in Japan, we could identify marginal parental living donors who have potential risks following LT, including heterozygous mothers with ornithine transcarbamylase deficiency, heterozygous protein C deficiency, heterozygous hypercholesterolemia, heterozygous protoporphyria, asymptomatic parental donors with paucity of intrahepatic bile duct, and human leukocyte antigen-homozygous parental donors.

show abstract

Frequency of HLA-Class I and Class II Homozygous cells in Japanese. HLA-Homozygous cells related to factor inducing transfusion-associated Graft Versus Host Disease.

Cited by 2 publications

References 1 publication

Successful engraftment after cord blood transplantation from an HLA‐homozygous donor (homo‐to‐hetero cord blood transplantation) in a primary myelofibrosis patient with broad HLA antibodies

Successful engraftment after cord blood transplantation from an HLA‐homozygous donor (homo‐to‐hetero cord blood transplantation) in a primary myelofibrosis patient with broad HLA antibodies

Marginal parental donors for pediatric living donor liver transplantation

Contact Info

Product

Resources

About